David S. Grayzel
CIK 1732786 · last filed 2026-07-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SURF price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
50 HAMPSHIRE ST., 8TH FLOOR
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QTTB | Director | — | $8.52 | — | $0 | 7 | 2026-07-21 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | 51,407 | $93.80 | $4.82M | $7.17M | 9 | 2024-06-07 |
| Surface Oncology, Inc. (SURF) Delisted | Director | 0 | $1.07 | $0 | -$43.04M | 10 | 2023-09-08 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| AVTE | By Atlas Venture Fund XII, L.P. | 50,992 | 99.2% | 2024-04-11 |
| By Atlas Venture Associates XII, L.P. | 414 | 0.8% | 2024-04-11 | |
| Total | 51,407 | |||
| SURF | Atlas Venture Fund IX, L.P. See Footnote |
0 | — | 2023-09-08 |
| Total | 0 | |||
| No longer reported | ||||
| Atlas IX See Footnote # |
2,945,453 | — | last 2020-12-21 | |
Recent Filings · Page 3 of 3
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-12-21 | Surface Oncology, Inc. (SURF) Delisted | Sell (S) | −1,700,000 | -$30.77M | EDGAR |
| 2020-06-12 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-10-03 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-07-02 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-06 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-04-23 | Surface Oncology, Inc. (SURF) Delisted | Mixed | +3,281,817 | $1.50M | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).